(AKRO) Akero Therapeutics - Performance 138.9% in 12m
Compare AKRO with Indices, Sectors and Commodities and Bonds. Who performs better in which timeframe?
Performance Rating
43.85%
#10 in Peer-Group
Rel. Strength
96.92%
#235 in Stock-Universe
Total Return 12m
138.88%
#5 in Peer-Group
Total Return 5y
98.07%
#13 in Peer-Group
| P/E | Value |
|---|---|
| P/E Trailing | - |
| P/E Forward | - |
| High / Low | USD |
|---|---|
| 52 Week High | 57.56 USD |
| 52 Week Low | 18.31 USD |
| Sentiment | Value |
|---|---|
| VRO Trend Strength +-100 | 90.54 |
| Buy/Sell Signal +-5 | 1.57 |
| Support / Resistance | Levels |
|---|---|
| Support | 45.4, 34.0, 30.5, 27.7 |
| Resistance | 49.0 |
12m Total Return: AKRO (138.9%) vs XBI (-13.2%)
5y Drawdown (Underwater) Chart
Top Performer in Biotechnology
Overall best picks of Peer Group - Selected by proven GARP Predictive Metrics, sorted by Growth Rating
| Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability | EPS CAGR |
|---|---|---|---|---|---|---|---|---|
| ABBV NYSE AbbVie |
6.84% | 15.6% | 146% | 75.7 | 15 | 0.39 | -26.0% | 14.2% |
| GILD NASDAQ Gilead Sciences |
3.25% | 66.1% | 80.1% | 22.9 | 13.8 | 0.23 | 28.0% | -3.71% |
| UTHR NASDAQ United Therapeutics |
8.95% | 12.5% | 161% | 12.4 | 11 | 1.43 | 74.6% | 16.1% |
| AMGN NASDAQ Amgen |
0.02% | -11% | 42.6% | 23.9 | 13 | 0.9 | 0.60% | 41% |
| LONN SW Lonza |
3.89% | 12.4% | 20.3% | 63.4 | 34.7 | 1.27 | 2.20% | -12.5% |
| BIM PA Biomerieux |
5.4% | 27.4% | -8.66% | 32.5 | 25.2 | 1.52 | -38.5% | -25.1% |
| KMDA NASDAQ Kamada |
6.72% | 32.6% | -8.16% | 24.8 | 24.4 | 0.97 | 48.1% | 3.93% |
| NBIX NASDAQ Neurocrine Biosciences |
19.8% | -14.2% | 1.4% | 39.2 | 23.6 | 0.27 | 18.7% | -34.3% |
Performance Comparison: AKRO vs XBI vs S&P 500
XBI (SPDR S&P Biotech ETF) is the Sector Benchmark for AKRO
| Total Return (including Dividends) | AKRO | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 28.35% | 5.06% | 13.42% |
| 3 Months | -6.73% | -13.48% | -2.55% |
| 12 Months | 138.88% | -13.24% | 11.09% |
| 5 Years | 98.07% | -23.08% | 109.60% |
| Trend Score (consistency of price movement) | AKRO | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | -9% | -39.2% | 93.5% |
| 3 Months | -44.1% | -69.2% | -14.5% |
| 12 Months | 83.3% | -62.5% | 46.8% |
| 5 Years | 16.2% | -53.9% | 84% |
| Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XBI | vs. S&P 500 |
|---|---|---|---|
| 1 Month | #28 | 22.17% | 13.16% |
| 3 Month | #58 | 7.80% | -4.29% |
| 12 Month | #6 | 175.33% | 115.04% |
| 5 Years | #11 | 157.50% | -5.50% |
FAQs
Does Akero Therapeutics (AKRO) outperform the market?
Yes,
over the last 12 months AKRO made 138.88%, while its related Sector, the SPDR S&P Biotech (XBI) made -13.24%.
Over the last 3 months AKRO made -6.73%, while XBI made -13.48%.
Performance Comparison AKRO vs Indeces and Sectors
Above 0 means better perfomance compared to Symbol in this Timeframe
AKRO vs. Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | 28.4% | 14.9% | 56.2% | 128% |
| US NASDAQ 100 | QQQ | 28.7% | 9.9% | 53.1% | 126% |
| German DAX 40 | DAX | 25.2% | 15.4% | 29.4% | 111% |
| Shanghai Shenzhen CSI 300 | CSI 300 | 28.3% | 23.2% | 55.4% | 130% |
| Hongkong Hang Seng | HSI | 28.1% | 13.5% | 43.6% | 128% |
| India NIFTY 50 | INDA | 27.5% | 26.4% | 52.7% | 137% |
| Brasil Bovespa | EWZ | 29.5% | 18.6% | 47.4% | 144% |
AKRO vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | 27.5% | 14% | 50.5% | 116% |
| Consumer Discretionary | XLY | 29.7% | 11.1% | 56.1% | 119% |
| Consumer Staples | XLP | 25% | 27.7% | 53% | 132% |
| Energy | XLE | 31.4% | 25% | 69.1% | 149% |
| Financial | XLF | 28.9% | 18.2% | 53.9% | 118% |
| Health Care | XLV | 25.5% | 29.1% | 62.9% | 147% |
| Industrial | XLI | 27.1% | 13% | 53.7% | 124% |
| Materials | XLB | 26.9% | 20.3% | 62.2% | 144% |
| Real Estate | XLRE | 27.6% | 25.4% | 60.2% | 129% |
| Technology | XLK | 29.7% | 6.3% | 56.4% | 131% |
| Utilities | XLU | 25.2% | 21.3% | 54.2% | 124% |
| Aerospace & Defense | XAR | 27% | 12.2% | 45.9% | 110% |
| Biotech | XBI | 23.8% | 23.3% | 70.8% | 152% |
| Homebuilder | XHB | 30.8% | 20.7% | 73.5% | 149% |
| Retail | XRT | 27.8% | 15.3% | 60% | 139% |
AKRO vs. Commodities
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Oil | USO | 29.3% | 29.9% | 62.6% | 150% |
| Natural Gas | UNG | 30.4% | 22.7% | 43.3% | 152% |
| Gold | GLD | 23.3% | 31.5% | 31% | 102% |
| Silver | SLV | 23.3% | 25.9% | 46.2% | 135% |
| Copper | CPER | 26.9% | 30.3% | 42.2% | 146% |
AKRO vs. Bonds
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| iShares 20+ Years Bond | TLT | 29.2% | 30.4% | 60% | 143% |
| iShares High Yield Corp. Bond | HYG | 28.1% | 25.9% | 53% | 131% |